Humacyte Posts Preclinical Data Of Small-Diameter Human Acellular Vessel In Bypass Grafting

Humacyte Inc HUMA has announced results from the first preclinical study of Humacyte's small-diameter (3.5mm) Human Acellular Vessel (HAV) in coronary artery bypass grafting (CABG). 

  • The HAV maintained patency and exhibited host-cell remodeling and regeneration in a non-human primate model.
  • In the preclinical study, the 3.5mm HAVs were implanted into primates following ligation of the native right coronary artery, and the primates were studied for six months. 
  • Humacyte plans to evaluate the safety and efficacy of these small-diameter HAVs in additional preclinical primate CABG studies designed to support first-in-human clinical trials. 
  • The 3.5mm diameter HAV has smaller product dimensions but is manufactured using a similar process as Humacyte's 6mm HAV system currently being evaluated in advanced-stage clinical trials in vascular trauma, arteriovenous access for hemodialysis, and peripheral arterial disease. 
  • Price Action: HUMA shares are down 5.47% at $4.76 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!